Cite

HARVARD Citation

    Waks, A. et al. (2022). Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. Journal for immunotherapy of cancer. 10 (10), p. . [Online]. 
  
Back to record